ALVO vs. FATE, LXEO, ITOS, REPL, TCRX, ADPT, TRML, OCGN, TSHA, and EDIT
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), iTeos Therapeutics (ITOS), Replimune Group (REPL), TScan Therapeutics (TCRX), Adaptive Biotechnologies (ADPT), Tourmaline Bio (TRML), Ocugen (OCGN), Taysha Gene Therapies (TSHA), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Alvotech (NYSE:ALVO) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Alvotech presently has a consensus price target of $12.67, indicating a potential downside of 6.17%. Fate Therapeutics has a consensus price target of $6.58, indicating a potential upside of 68.80%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Alvotech.
Alvotech has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
In the previous week, Fate Therapeutics had 7 more articles in the media than Alvotech. MarketBeat recorded 12 mentions for Fate Therapeutics and 5 mentions for Alvotech. Fate Therapeutics' average media sentiment score of 0.17 beat Alvotech's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Fate Therapeutics has lower revenue, but higher earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alvotech has a net margin of -967.97% compared to Fate Therapeutics' net margin of -2,933.79%. Alvotech's return on equity of 0.00% beat Fate Therapeutics' return on equity.
97.5% of Fate Therapeutics shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Fate Therapeutics received 475 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 68.62% of users gave Fate Therapeutics an outperform vote while only 36.36% of users gave Alvotech an outperform vote.
Summary
Fate Therapeutics beats Alvotech on 13 of the 17 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
